PHENIX trial: what clinicians have said so far
Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)
- NCT02642471 ↗
- Active, not recruiting
- Sun Yat-sen University
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on PHENIX (early-stage cervical cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 13 indexed sources
Automated from all 13 indexed sources (Oct 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether sentinel node biopsy alone matches added pelvic lymphadenectomy for disease-free and cancer-specific survival
- Whether omitting lymphadenectomy reduces lymphedema, lymphocyst and other surgical morbidity
- Whether sentinel node biopsy alone should replace pelvic lymphadenectomy in early-stage cervical cancer practice
- Whether the comparison holds in both the SLN-negative and SLN-positive cohorts
Indexed commentary on PHENIX so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X, typically up to 35 once built | |
| 4 YouTube videos, typically up to 18 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)
- Phase
- Phase not applicable
- Status
- Active, not recruiting
- Conditions
- Cervical Cancer; Surgery; Quality of Life
- Interventions
- no systematic pelvic lymphadenectomy
- Arms
- Arm 1 · Experimental
- Arm 2 · No intervention
- Arm 3 · Experimental
- Arm 4 · No intervention
- Enrollment
- 1,080 (estimated)
- Primary outcomes
- Disease free survival in PHENIX-I
- Disease free survival in PHENIX-II
- Sponsor
- Sun Yat-sen University
- Start
- Dec 31, 2015
- Primary completion
- Dec 31, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT02642471 · updated Dec 16, 2024
Publications
linked from the registry- Tu H, Huang H, Li Y, Chen X, Wang C, Zheng M, Zhang Y, Zhao W, Feng Y, Wan T, Huang Y, Yu A, Lu W, Xiao J, Shan W, Zhang P, Zhu C, Wang D, Zhou H, Li J, Kong B, Feng W, Wang X, Luo R, Huang X, Li J, Lin Z, Yao S, Liu J; PHENIX Investigators. Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer. N Engl J Med. 2025 Oct 16;393(15):1463-1474. doi: 10.1056/NEJMoa2506267. PubMed 41092328
- Tu H, Huang H, Xian B, Li J, Wang P, Zhao W, Chen X, Xie X, Wang C, Kong B, Xiao J, Zhang P, Liu J; PHENIX Investigators and the CSEM group. Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010). Int J Gynecol Cancer. 2020 Nov;30(11):1829-1833. doi: 10.1136/ijgc-2020-001857. Epub 2020 Sep 24. PubMed 32973117